Reported
Lowest–highest estimate
The chart could not be loaded. Try again or view the figures below.
| Value | YoY | Lowest–highest | Analysts | |
|---|---|---|---|---|
Clinuvel Pharmaceuticals Ltd
XMUN:UR9
Clinuvel Pharmaceuticals Ltd
XMUN:UR9
Price:
4.576
EUR
Market Closed
Market Cap:
€690.6m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
C
|
Clinuvel Pharmaceuticals Ltd
XMUN:UR9
|
AU |
|
S
|
Salesforce Inc
F:FOO
|
US |
|
1
|
1CM Inc
F:IQ70
|
CA |
|
Amadeus IT Group SA
F:AI3A
|
ES |
|
U
|
UL Solutions Inc
NYSE:ULS
|
US |
|
H
|
Harley-Davidson Inc
XMUN:HAR
|
US |
Wall St Price Targets
UR9 Price Forecast
Based on 8 analysts
Based on 8 analysts
+100% Upside
from
€4.576
today
Clinuvel Pharmaceuticals Ltd (UR9)’s 12-month stock price forecast through October 2027 has a consensus target of €9.164, implying 100% upside. The forecast is based on price targets from 8 Wall Street analysts.
UR9 Analyst Rating
No ratings yet
No ratings yet
Clinuvel Pharmaceuticals Ltd Competitors:
Price Targets
Price Targets
Why do you have more estimates than other sites?
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is UR9's stock price target?
Price Target
9.164
EUR
9.164
EUR
According to Wall Street analysts, the average 1-year price target for UR9 is 9.164 EUR with a low forecast of 5.986 EUR and a high forecast of 25.691 EUR.
What is the Revenue forecast for Clinuvel Pharmaceuticals Ltd?
Projected CAGR
15%
15%
Over the last 14 years, the compound annual growth rate for Revenue has been 36%. The projected CAGR for the next 3 years is 15%.
What is the Gross Profit forecast for Clinuvel Pharmaceuticals Ltd?
Projected CAGR
13%
13%
The compound annual growth rate for Gross Profit over the next 3 years is 13%.
What is the Operating Income forecast for Clinuvel Pharmaceuticals Ltd?
Projected CAGR
15%
15%
The compound annual growth rate for Operating Income over the next 3 years is 15%.
What is the Pre-Tax Income forecast for Clinuvel Pharmaceuticals Ltd?
Projected CAGR
17%
17%
The compound annual growth rate for Pre-Tax Income over the next 3 years is 17%.
What is the Net Income forecast for Clinuvel Pharmaceuticals Ltd?
Projected CAGR
16%
16%
The compound annual growth rate for Net Income over the next 3 years is 16%.